US4722938A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for using musculoskeletal relaxants
Assignee: Analgesic Associates
•
Filing: 1986-01-02
•
Granted: 1988-02-02
•
Expires: 2006-01-02
Abstract
Abstract Novel pharmaceutical analgesic, anti-inflammatory and skeletal muscle relaxant compositions and methods of using same comprising an analgesically and anti-inflammatory effective amount of at least one non-steroidal anti-inflammatory drug other than aspirin, acetaminophen and phenacetin, in combination with an effective amount of a skeletal muscle relaxant.
Inventors
- 👤 Abraham Sunshine
- 👤 Eugene M. Laska
- 👤 Carole E. Siegel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/42; A61K31/21; A61K31/27; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/55
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
100 words
A method for the treatment of musculoskeletal disorders in a mammalian organism in need of such treatment, comprising administering to such organism a symptom relieving analgesically and anti-inflammatorily effective amount of (i) at least one of the propionic acid NSAIDs, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, ibuprofen aluminum, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, or pharmaceutically acceptable salt thereof, in combinatory immixture with a skeletal muscle relaxing amount of (ii) at least one of the glycerylmonoether SMRS, methocarbamol, mephenesin, mephenesin carbamate, mephenesin acid succinate, chlorphenesin carbamate, or pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
100 words
A method for the treatment of musculoskeletal disorders in a mammalian organism in need of such treatment, comprising administering to such organism a symptom relieving analgesically and anti-inflammatorily effective amount of (i) at least one of the propionic acid NSAIDs, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, ibuprofen aluminum, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, or pharmaceutically acceptable salt thereof, in combinatory immixture with a skeletal muscle relaxing amount of (ii) at least one of the glycerylmonoether SMRS, methocarbamol, mephenesin, mephenesin carbamate, mephenesin acid succinate, chlorphenesin carbamate, or pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
30 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, said NSAID (i) comprising ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen, fluprofen, or pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
23 words
The method for the treatment of musculoskeletal disorders as defined by claim 2, said NSAID (i) comprising ibuprofen or pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
23 words
The method for the treatment of musculoskeletal disorders as defined by claim 2, said NSAID (i) comprising naproxen or pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
23 words
The method for the treatment of musculoskeletal disorders as defined by claim 2, said NSAID (i) comprising ketoprofen or pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
23 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, said SMR (ii) comprising methocarbamol or pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
26 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, said combinatory immixture further comprising a pharmaceutically acceptable non-toxic carrier, diluent or excipient.
Claim 9
Dependent Claim
25 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising oral administration of a unit dosage amount of said combinatory immixture.
Claim 10
Dependent Claim
25 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising parenteral administration of a unit dosage amount of said combinatory immixture.
Claim 11
Dependent Claim
25 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising rectal administration of a unit dosage amount of said combinatory immixture.
Claim 12
Dependent Claim
28 words
The method for the treatment of musculoskeletal disorders as defind by claim 1, said combinatory immixture comprising from about 12.5 mg to 900 mg of said NSAID (i).
Claim 13
Dependent Claim
33 words
The method for the treatment of musculoskeletal disorders as defined by claim 6, said combinatory immixture comprising from about 200 mg to 2000 mg of said methocarbamol SMR or pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
31 words
The method for the treatment of musculoskeletal disorders as defined by claim 3, said combinatory immixture comprising from about 100 mg to 400 mg of ibuprofen or pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
25 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising sustainedly controlledly administering a unit dosage amount of said combinatory immixture.
Claim 16
Dependent Claim
35 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising eliciting a musculoskeletal relaxing and analgesic/anti-inflammatory response in a mammalian organism afflicted with muscle spasms and the symptoms of rheumatoid arthritis.
Claim 17
Dependent Claim
34 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising eliciting a musculoskeletal relaxing and analgesic/anti-inflammatory response in a mammalian organism afflicted with muscle spasms and the symptoms of osteoarthritis.
Claim 18
Dependent Claim
30 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising eliciting a musculoskeletal relaxing and analgesic/anti-inflammatory response in a mammalian organism afflicted with skeletal muscle spasms.
Claim 19
Dependent Claim
30 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising eliciting a musculoskeletal relaxing and analgesic/anti-inflammatory response in a mammalian organism afflicted with lower back pain.
Claim 20
Dependent Claim
29 words
The method for the treatment of musculoskeletal disorders as defined by claim 1, comprising eliciting a musculoskeletal relaxing and analgesic/anti-inflammatory response in a mammalian organism afflicted with disk syndrome.
References Cited (Backward Citations)
FR2121529A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-01 | 1991-08-03 | 1992-02-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-01 | 1995-08-03 | 1996-02-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-01 | 1999-08-03 | 2000-02-02 | $7700.00 | Window Closed / Lapsed |